Principal Financial Group
ADCT icon

Principal Financial Group’s ADC Therapeutics ADCT Stock Holding History

Principal Financial Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400,300
Closed -$1.54M – 2465
2022
Q4 		$1.54M Sell
400,300
-100
-0% -$400 ﹤0.01% 1807
2022
Q3 		$1.93M Sell
400,400
-5,702
-1% -$41.3K ﹤0.01% 1717
2022
Q2 		$3.23M Buy
406,102
+100,856
+33% +$954K ﹤0.01% 1693
2022
Q1 		$4.48M Buy
305,246
+2,012
+0.7% +$31.9K ﹤0.01% 1696
2021
Q4 		$6.13M Buy
303,234
+11,429
+4% +$276K ﹤0.01% 1597
2021
Q3 		$7.92M Sell
291,805
-3,358
-1% -$86K 0.01% 1512
2021
Q2 		$7.19M Buy
295,163
+75,664
+34% +$1.76M ﹤0.01% 1578
2021
Q1 		$5.36M Buy
219,499
+6,525
+3% +$189K ﹤0.01% 1647
2020
Q4 		$6.82M Sell
212,974
-1,406
-0.7% -$46.1K 0.01% 1441
2020
Q3 		$7.07M Buy
214,380
+61,293
+40% +$2.65M 0.01% 1285
2020
Q2 		$7.17M Buy
+153,087
New +$5.81M 0.01% 1247

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Principal Financial Group's ADCT Position: Q1 2023 in Review

Principal Financial Group sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 400,300 shares — an estimated $1.54M sold.

Principal Financial Group first reported a position in ADCT in Q2 2020 and held it in 11 quarters. The position peaked at $7.92M in Q3 2021. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

  • Principal Financial Group reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Principal Financial Group sold 400,300 ADC Therapeutics shares in Q1 2023, an estimated $1.54M.
  • Principal Financial Group first reported a position in ADC Therapeutics in Q2 2020 and held it in 11 quarters.
  • Principal Financial Group's ADC Therapeutics position peaked at $7.92M in Q3 2021.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on Principal Financial Group's 13F filing for Q1 2023, filed 9 May 2023.